Regulatory mechanisms, functions, and clinical significance of CircRNAs in triple-negative breast cancer

Lijuan Lyu1,2†, Shizhen Zhang3†, Yujiao Deng1,2, Meng Wang2, Xinyue Deng1, Si Yang1,2, Ying Wu1,2 and Zhijun Dai1,2*

Abstract
Circular RNAs (circRNAs) are a new class of endogenous regulatory RNAs characterized by covalently closed cyclic structure lacking poly-adenylated tails, and are capable of regulating gene expression at transcription or post-transcription levels. Recently, plentiful circRNAs have been discovered in breast cancer and some circRNAs expression profiles are specifically involved in the triple-negative breast cancer (TNBC). TNBC is a type of malignant tumor defined by the lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. Considering its clinical characteristics of high invasion, metastasis, poor prognosis, and lack of effective response to conventional chemotherapies or targeted therapies, it could be a promising option to discover specific circRNAs as new targets for TNBC treatment. Meanwhile, accumulating evidence has demonstrated that circRNAs are dysregulated in TNBC tissues and are correlated with clinicopathological features and prognosis of TNBC patients. Furthermore, looking for circRNAs with high specificity and sensitivity will provide a new opportunity for the early diagnosis, clinical treatment, and prognosis monitoring of TNBC. Herein, we reviewed the biogenesis, regulatory mechanisms, and biological functions of circRNAs in TNBC and summarized the relationship between circRNAs expression and the clinicopathology, diagnosis, and prognosis of patients with TNBC.

Keywords: CircRNAs, Triple-negative breast cancer, Biogenesis, Biological functions, Regulation mechanisms, Diagnosis, Clinicopathology, Prognosis

Background
Breast cancer (BC) is the most common malignant disease among females and seriously threatens the health of women worldwide [1, 2]. Triple-negative breast cancer (TNBC) is the subtype of BC with the highest recurrence, metastasis, and mortality rate. It is pathologically characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [3, 4]. TNBC accounts for approximately 15% of all BCs, with typically more aggressive characteristics and lack of effective targeted treatment options [5, 6]. Therefore, early detection and feasible targeted therapy are especially important for TNBC patients. Traditionally, many clinicopathological features, such as tumor size, lymph node status, and histological grade, are associated with patient outcomes and are used to predict patient prognosis [7]. Several newly identified biomarkers, such as tumor-associated macrophages (TAMs), microRNAs (miRNAs), and long non-coding RNA (lncRNAs), also have important prognostic values [8]. In recent years, circular RNAs (circRNAs) have attracted a lot of attention due to their key roles involved in human cancers, including TNBC.
CircRNA was first observed in the 1976 by Sanger et al. in plant-infected viroids by electron microscopy and were considered pathogenic because of their structural similarity to viruses [9]. They were later discovered in eukaryotes and were thought to be a result of splicing errors for several decades after the 1970s [10, 11]. However, more recent studies of circRNAs in drosophila, mouse, and other eukaryotes indicate that these RNA transcripts are evolutionarily conserved and thus are not simple artifacts of faulty splicing [12, 13]. In addition, with the advances in sequencing technology and bioinformatics analyses, the abundance and diversity of circRNAs therefore can be easily identified [14, 15]. High-throughput RNA sequencing (RNA-seq) and microarray are widely used technology to annotate new RNA species and quantify RNA abundance, which have identified the majority of circRNAs in human cells. Besides, increasing bioinformatic algorithms have been developed for identifying circRNAs, such as circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice [16]. The mainly validation methods for circRNA expression are quantitative real-time PCR (qRT-PCR) and Northern blotting, and Northern blotting is a more stringent circRNA validation method than qRT-PCR, given its straightforward procedure with no reverse transcription and amplification steps [17].

Researchers have identified that circRNAs possess significant roles in regulation of multiple factors at transcription or post-transcriptional levels in mammalian cells, and dysregulations of circRNAs can affect genes expression and lead to diseases [18–20], including cancer [21, 22]. Many studies using microarray and RNA-seq revealed that circRNAs can be frequently detected in BC [23, 24]. Especially, recent studies depicted the systematic profiling and characterization of circRNA expression pattern in different subtypes of BC [25, 26], and such subtype-specific set of circRNAs may be used for distinguishing the tumor subtypes, suggesting that circRNAs can be exploited as novel molecular biomarkers. Notably, more and more evidence have indicated that dysregulation of circRNAs participate in carcinogenesis and progression of TNBC, as a result, certain circRNAs could be potentially diagnostic and prognostic biomarkers or therapeutic targets for TNBC [27–29]. Hence, we concentrated on recent findings related to the role of circRNAs in TNBC and summarized their potential clinical implications in TNBC, such as identification of biomarkers for early and differential diagnosis, prognosis, and prediction of response to specific therapies.

The biogenesis of circRNAs
CircRNAs are derived from precursor messenger RNAs (pre-mRNAs), which are transcribed by RNA polymerase II, and characterized by circular shapes resulting from covalently closed continuous loops [30, 31]. With their unique structures, circRNAs are resistant to exonuclease RNase Rand, which makes them more conservative and stable than their linear counterparts [32]. CircRNAs are mainly divided into four types according to their various components and circularization mechanism, including exon circRNAs (EcircRNAs), circular intronic RNAs (ciRNAs), exon–intron circRNAs (EIciRNAs), and intergenic circRNAs or fusion circRNAs (f-circRNAs) [33]. EcircRNAs, consisting of only one exon or multiple quantities of exons and forming through a shearing process called “head-to-tail” or “backsplicing”; make up over 80% of circRNAs and mostly exist in the cytoplasm [34]. EIciRNAs are predominantly located in the nucleus and is circularized in the form of retaining introns between exons [35]. There are currently three models, namely intron-pairing-driven circularization, RNA-binding-protein (RBP)-dependent circularization, and lariat-driven circularization, that have been recognized to elaborate the origination of EcircRNAs and EIciRNAs (Fig. 1) [36]. Notably, a newly discovered type of circRNA termed ciRNAs, are derived from introns and mainly found in the nucleus. There are also three hypothetical models explaining the formation of ciRNAs, including circular RNA from group I introns, circular RNA from group II introns, and intron RNA lariat (Fig. 2) [36, 37]. The f-circRNAs are identified by applying CIRI (an algorithm for de novo circular RNA identification) and contain two intronic circRNA fragments flanked by GT-AC splicing signals acting as the splice donor and acceptor of the circular junction while forming an integrated circRNA (Fig. 1d) [38].

Regulatory mechanisms of circRNAs in TNBC
CircRNAs are a novel class of abundant, stable and ubiquitous noncoding RNAs with diverse regulatory roles in tumor cells, including serving as miRNA sponges, binding to RBPs, modulating genes transcription, competing with linear splicing, translating into protein, and so on [20, 39]. In TNBC, the circRNAs has not yet been found to modulate genes transcription and compete with linear splicing. The regulatory mechanisms of circRNAs involved in TNBC cells are depicted in Fig. 3 and Table 1, which summarized most circRNAs involved in TNBC.

CircRNAs serve as miRNA sponges
MiRNAs negatively regulate the gene expression of messenger RNAs (mRNAs) through direct base pairing to target sites in mRNA 3′ untranslated regions, eventually leading to decreased mRNA stability and translation suppression [40]. The competing endogenous RNA (ceRNA) hypothesis showed that other RNAs with miRNA target sites can compete with mRNAs for miRNA binding [41].
Fig. 1  Biogenesis mechanism of EcircRNA and ElciRNA circRNAs. a Intron-pairing-driven circularization: the upstream intron pairs with the downstream intron, then the 2′-hydroxyl of the upstream intron reacts with the 5′-phosphate of the downstream intron, followed by the 3′-hydroxyl of the 3′-exon reacting with the 5′-phosphate of the 5′-exon; b RBPs-dependent circularization: RNA binding proteins (RBPs) bind the upstream and downstream introns and are attracted to each other, and form a bridge between the introns, then the 2′-hydroxyl of the upstream intron reacts with the 5′-phosphate of the downstream intron, followed by the 3′-hydroxyl of the 3′-exon reacting with the 5′-phosphate of the 5′-exon; c Lariat-driven circularization: Folding of a region of pre-RNA can result in exon skipping; furthermore, the splice donor in 3′ end of exon 1 and the splice acceptor in 5′ end of exon 4 are covalently joined together to form a lariat containing exon 2 and exon 3; d Fusion-circRNAs contain two exon circRNA fragments flanked by GT-AC splicing signals acting as the splice donor and acceptor of the circular junction while forming an integrated circRNA.

Fig. 2  Biogenesis mechanism of intronic circRNA. a Circular RNA from group I introns: first, an exogenous guanosine (G) attacks the 5′-terminus of the intron as nucleophile and the 5′-exon is cut off due to the transesterification; Second, the 3′-hydroxyl of the free exon attacks the 5′-terminus of the 5′-exon as nucleophile, producing a linear intron; Third, a 2′-hydroxyl close to the 3′-terminus of the linear intron attacks a phosphodiester bond close to the 5′-terminus, producing an RNA lariat circularized with 2′,5′-phosphodiester and releasing the 5′-terminal sequence; b Circular RNA from group II introns: the pre-mRNA releases the 3′-exon, then the 2′-hydroxyl of the 3′-terminus attacks the 5′-terminus of the intron, producing an circular RNA circularized with 2′,5′-phosphodiester; c Intron RNA lariat: the pre-mRNA is spliced by a spliceosome, producing an RNA lariat circularized with 2′,5′-phosphodiester.
Indeed, most circRNAs, containing a large number of different types of miRNA response elements, are located in the cytoplasm with huge miRNA-binding capacity and have been found to interact with miRNA and serve as miRNA sponges to remove the inhibitory effect of miRNA on its target genes in cancer [42–44].

Most of the circRNAs currently reported in TNBC serve as miRNA sponges (Fig. 3a). For instance, ciRS-7, an earlier discovered circRNA in TNBC, contains 20 miR-1299-binding sites and functions as a ceRNA of miR-1299 to enhance the expression of the matrix metalloproteinase family members, thereby contributing to the high migration and invasion properties of TNBC cells [45]. CircEPSTI1 promotes TNBC proliferation and apoptosis by upregulating BCL11A expression via binding to miR-4753 and miR-6809 [46]. Zeng et al. [47] reported that circANKS1B abundantly sponged miR-148a-3p and miR-152-3p to increase the expression of transcription factor USF1. Moreover, the splicing factor ESRP1, regulated by USF1, can promote circANKS1B biogenesis in TNBC. CircTADA2A-E6 preferentially acts as an miR-203a-3p sponge to restore the expression of miRNA target gene SOCS3, resulting in a less aggressive oncogenic phenotype [48]. Zheng et al. demonstrated that circSEPT9 could regulate the expression of LIF via sponging miR-637 and activating the LIF/Stat3 signaling pathway involved in the progression of TNBC. More importantly, they discovered that E2F1 and EIF4A3 enhance the expression of circSEPT9 by binding to the SEPT9 promoter and pre-mRNA [49]. CircGFRA1 was found not only could upregulate TLR4 via sponging for miR-361-5p, thus affecting the sensitivity of TNBC cells to paclitaxel (PTX) [50], but also upregulate its parent gene GFRA1 expression through sponging miR-34a, thus promoting proliferation and inhibiting apoptosis of TNBC cells [29]. Likewise, circKIF4A and circITCH were proved to upregulate its parental genes via acting as sponges for miRNAs thereby mediating TNBC progress [51, 52]. Additionally, more miRNA-sponge functions of circRNAs have been and are being validated in TNBC, including circUBAP2/miR-661/MTA1 [53], circPLK1/miR-296-5p/PLK1 [54], circTFCP2L1/miR-7/PAK1 [55], circAHNAK1/miR-421/RASA1 [56], circAGFG1/miR-195-5p/CCNE1 [57], circZEB1/miR-448/eEF2K [58], circGNB1/miR-141-5p/IGF1R [59], circRPHH1/miR-556-5p/YAP1 [60], circCDYL/miR-190a-3p/TP53INP1 [61], circEIF3M/miR-33a/cyclinD1 [62], circUBE2D2/miR-512-3p/CDCA3 [63], and circPGAP3/miR-330-3p/Myc [64].
### Table 1 Summary of dysregulated circRNAs in TNBC

| CircRNAs       | Location       | Technique/cohort          | Method      | Sample type                                      | Expression in tumor | Roles        | Biomarkers | AUC | Survival Functions | Mechanism | Gene symbol | Pathway | References |
|----------------|----------------|---------------------------|-------------|-------------------------------------------------|---------------------|--------------|------------|-----|------------------|-----------|-------------|---------|------------|
| circGFRA1      | cytoplasm      | MDA-MB-231/PTX            | qRT-PCR     | MDA-MB-231/PTX                                  | Up in MDA-MB-231/PTX | Oncogenic   | Prediction of therapy response | NR | NR              | Increase the resistance of TNBC cells to PTX | Sponge miR-361-5p | LTA4 | NR         | [50]   |
| circRPPH1      | cytoplasm      | GSE101123/20 TNBC versus 20 N | qRT-PCR     | TNBC tissues and cells                           | Up                  | Oncogenic   | Prediction of therapy response | NR | NR | NR | Progression and metastasis | Sponge miR-556-5p | YAP1 | NR | [60] |
| circSEPT9      | cytoplasm      | RNA-seq of 4 TNBC versus 4 N/60 TNBC versus 60 N/80 TNBC | qRT-PCR, ISH | TNBC tissues and cells                           | Up                  | Oncogenic   | Diagnosis and prognosis | 0.711 | OS | Proliferation, metastasis, apoptosis, and autophagy | Sponge miR-637 | LIF | NR | [49] |
| circLARP4      | NR             | 283 BC versus 283 N 65 TNBC versus 65 N | qRT-PCR     | TNBC tissues and cells                           | Down                | Antitumor   | Prediction of therapy response | NR | NR | Inhibit the resistance of TNBC cells to DOX | NR | NR | NR | [89] |
| circUSP42      | NR             | RNA-seq of TNBC versus adjacent tissues/30 TNBC versus 30 N | qRT-PCR     | TNBC tissues                                     | Down                | Antitumor   | Prognosis | NR | OS, DFS | Increase the resistance of TNBC cells to PTX | Sponge Let-7a-5p | DUSP7 | NR | [88] |
| circABC810     | NR             | MDA-MB-231/PTX            | qRT-PCR     | MDA-MB-231/PTX                                  | Up in MDA-MB-231/PTX | Oncogenic   | Prediction of therapy response | NR | NR | Increase the resistance of TNBC cells to PTX | Sponge miR-190a-3p | TP53NP1 | NR | [61] |
| circCDYL       | NR             | BC versus N               | qRT-PCR     | BC tissues and TNBC cells                        | Down                | Antitumor   | Prediction of therapy response | NR | NR | Proliferation, migration, and invasion | Sponge miR-448 | eEF2k | NR | [58] |
| circZEB1       | NR             | 30 TNBC versus 30 N       | RT-qPCR     | TNBC tissues, cells                             | Up                  | Oncogenic   | Prognosis | NR | OS, DFS | Proliferation and metastasis | Sponge miR-141-5p | IGFR1 | NR | [59] |
| circGNB1       | cytoplasm      | Microarray/222 TNBC       | RT-qPCR     | TNBC tissue, cells                              | Up                  | Oncogenic   | Prognosis | NR | OS | Proliferation and metastasis | Sponge miR-2682 | NR | NR | [78] |
| hsa_circ_0131242 | NR          | Microarray of TNBC versus normal tissues/30 TNBC versus 30 N/120 TNBC | RT-qPCR     | TNBC tissue, cells                              | Up                  | Oncogenic   | Prognosis | NR | OS | Proliferation, metastasis, cell cycle, and apoptosis | Sponge miR-33a | CCND1 | NR | [62] |
| circBIF3M      | cytoplasm      | RNA-seq of 3 TNBC versus 3 N/20 TNBC versus 20 N | RT-qPCR     | TNBC tissue, cells                              | Up                  | Oncogenic   | Prognosis | NR | NR | Proliferation, metastasis, cell cycle, and apoptosis | Sponge miR-33a | CCND1 | NR | [62] |
| CircRNAs | Location | Technique/ cohort | Method | Sample type | Expression in tumor | Roles | Biomarkers | AUC | Survival | Functions | Mechanism | Gene symbol | Pathway | References |
|----------|----------|-------------------|--------|-------------|--------------------|-------|-------------|-----|----------|-----------|-----------|-------------|---------|------------|
| circHER2 | cytoplasm | RNA-seq of 5 TNBC versus 5N/59 TNBC versus 59 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis and prediction of therapy response | NR | OS | Proliferation and invasion, circHER2 expressing TNBC are sensitive to Pertuzumab | Encode a novel HER2 variant HER2–103 | HER2–103 | Promote EGFR/HER3 interaction and activation | [75] |
| circPGAP3 | cytoplasm | 86 TNBC versus 86 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS, DFS | Proliferation and metastasis | Sponge miR-330-3p | myc | NR | [64] |
| circUBE2D2 | cytoplasm | 66 TNBC versus 66 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis and prediction of therapy response | NR | OS | Proliferation and metastasis, increase the resistance of TNBC cells to DOX | Sponge miR-512-3p | CDCA3 | NR | [63] |
| circRAD18 | cytoplasm | Microarray of TNBC versus adjacent tissues/31 TNBC versus 31 N/126 TNBC | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Diagnosis and prognosis | 0.752 | OS | Proliferation, metastasis, and apoptosis | Sponge miR-203a/3164 | IGF1 and FGFR2 | NR | [78] |
| hsa_circ_0003320 | cytoplasm | RNA-seq of 4 TNBC versus 4N/20 TNBC versus 20 N | RT-Q-PCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | NR | Proliferation, cell cycle, and apoptosis | NR | LIF + P-STAT3 | activate LIF-STAT3 pathway | [80] |
| hsa_circ_069718 | NR | Microarray of TNBC versus adjacent tissues/35 TNBC versus 35 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS | Proliferation and invasion | NR | β-catenin, c-myc, and cyclin D1 | Activate Wnt/β-catenin pathway | [81] |
| circFBXW7 | cytoplasm | 473 TNBC | RT-qPCR | TNBC tissue, cells | Down | Antitumor | Prognosis | NR | OS, DFS | Proliferation and metastasis | Sponge miR-197-3p and encode the FBXW7-185aa protein | FBXW7 | NR | [74] |
| circCDR1as | NR | MDA-MB-231/5-Fu | RT-qPCR | MDA-MB-231/5-Fu | Up | Oncogenic | Prediction of therapy response | NR | NR | Increase the resistance of TNBC cells to 5-FU | Sponge miR-7 | NR | NR | [97] |
| CircRNAs       | Location | Technique/cohort | Method  | Sample type | Expression in tumor | Roles       | Biomarkers | AUC | Survival | Functions                        | Mechanism                                      | Gene symbol | References  |
|---------------|----------|----------------|---------|-------------|---------------------|-------------|------------|-----|----------|----------------------------------|-----------------------------------------------|------------|------------|
| circAGFG1     | cytoplasm| RNA-seq of 4   | RT-qPCR | TNBC tissue, cells | Up                  | Oncogenic   | Diagnosis and prognosis | 0.767 | OS       | Proliferation, metastasis, cell cycle, and apoptosis | Sponge miR-195-5p                             | CCNE1      | [57]       |
|               |          | TNBC versus 4 N/40 TNBC versus 40 N/80 TNBC | ISH     |             |                     |             |                         |       |          |                                  |                                              |            |            |
| hsa_circ_0058514 | NR      | RNA-seq of 4   | RTFQ-PCR | TNBC tissue, cells | Up                  | Oncogenic   |                         | NR   | NR      | Proliferation, metastasis, cell cycle, and apoptosis |                                  | NR         | [82]       |
|               |          | TNBC versus 4 N/20 TNBC versus 20 N |             |             |                     |             |                         |       |          |                                  |                                              |            |            |
| circTADA2A-66 | cytoplasm| Microarray of 8 | RT-qPCR | TNBC tissue, cells | Down                | Antitumor   | Diagnosis and prognosis | 0.8554 | OS, DFS  | Proliferation and metastasis             | Sponge miR-203a-3p                            | SOCS3      | [48]       |
|               |          | specimens (4 TNBC and 4 luminal A) versus 3 normal tissues/178 BC versus 16 N /115 TNBC |             |             |                     |             |                         |       |          |                                  |                                              |            |            |
| circAHNAK1    | cytoplasm| Microarrays/20 | RT-qPCR | TNBC tissue, cells | Down                | Antitumor   | Diagnosis and prognosis | 0.72  | OS, DFS  | Proliferation and metastasis             | Sponge miR-421                                | RASA1      | [56]       |
|               |          | TNBC versus 20 N/136 TNBC |             |             |                     |             |                         |       |          |                                  |                                              |            |            |
| circTCH       | NR       | 275 BC versus 68 N/91 TNBC | RT-qPCR | TNBC tissue, cells | Down                | Antitumor   | Prognosis                | NR   | OS      | Proliferation and metastasis             | Sponge miR-214/ miR-17                         | ITCH       | [52]       |
|               |          |                                                           |             |             |                     |             |                         |       |          |                                  |                                              |            |            |
| circTFCP2L1   | cytoplasm| Microarray of 3 | RT-qPCR | TNBC tissue, cells | Up                  | Oncogenic   | Prognosis                | NR   | DFS     | Proliferation and migration             | Sponge miR-7                                   | PAK1       | [55]       |
|               |          | TNBC versus 3 N/32 TNBC versus 32 N/234 |             |             |                     |             |                         |       |          |                                  |                                              |            |            |
| circKIF4A     | cytoplasm| Microarray/240 | RT-qPCR | TNBC tissue, cells | Up                  | Oncogenic   | Prognosis                | NR   | OS, DFS  | Proliferation and metastasis             | Sponge miR-375                                | KIF4A      | [51]       |
|               |          | TNBC |             |             |                     |             |                         |       |          |                                  |                                              |            |            |
| circAMOTL1    | NR       | MDA-MB-231/ PTX | qRT-PCR | MDA-MB-231/ PTX | Up in MDA-MB-231/ PTX | Oncogenic   | Prediction of therapy response | NR   | NR      | Increase the resistance of TNBC cells to PTX |                                  | BCL2, BAX and AKT pathway,                     |            | [96]       |
|               |          | MDA-MB-231/ PTX |             |             |                     |             |                         |       |          |                                  |                                              |            |            |
| circDMMAC     | cytoplasm| MDA-MB-231/ DOX | qRT-PCR | MDA-MB-231/ DOX | Down MDA-MB-231/ DOX | Antitumor   | Prediction of therapy response | NR   | NR      | Decreased the resistance of TNBC cells to doxorubicin | Sponge miR-548p                              | PBLD       | [90]       |
|               |          | MDA-MB-231/ DOX |             |             |                     |             |                         |       |          |                                  |                                              |            |            |
| CircRNAs   | Location | Technique / cohort | Method     | Sample type | Expression in tumor | Roles     | Biomarkers | AUC | Survival | Functions | Mechanism | Gene symbol | Pathway       | References |
|-----------|----------|--------------------|------------|-------------|--------------------|-----------|------------|-----|----------|-----------|-----------|-------------|---------------|------------|
| circPLK1  | cytoplasm | Microarray of four cell lines (MDA-MB-231, MDA-MB-468, BT5-49 versus MCF-10A) /57 TNBC versus 57 N/240 TNBC | RT-qPCR    | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS, DFS | Proliferation and metastasis | Sponge miR-296-5p | PLK1 | NR | [54] |
| circANKS1B | cytoplasm | RNA-seq of 3 TNBC versus 3 N/20 TNBC versus 20 N/165 BC versus 40 N | RT-qPCR    | BC tissue, cells | Up | Oncogenic | Prognosis | NR | OS | Invasion and metastasis | Sponge miR-148a/152-3p | USF1 | Activate of TGF-β1 signaling pathway | [47] |
| circUBAP2 | cytoplasm | 78 TNBC versus 78 N | RT-qPCR    | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS | Proliferation, invasion and metastasis | Sponge miR-661 | MTA1 | NR | [53] |
| circ-cfDS-7 | cytoplasm | 32 TNBC versus 32 N | RT-qPCR    | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | NR | Invasion and metastasis | Sponge miR-1299 | MMPs | NR | [45] |
| circMTO1  | nucleus  | MDA-MB-231/monastrol | qRT-PCR    | MDA-MB-231/monastrol | Down MDA-MB-231/monastrol | Antitumor | Prediction of therapy response | NR | NR | Reverses the resistance of TNBC cells to monastrol | Sponge miR-4753/6809 | BCL11A | NR | [46] |
| circEPSTI1 | NR       | Microarray of 3 TNBC versus 3 N/37 TNBC versus 30 N/240 TNBC | RT-qPCR, ISH | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS, DFS | Proliferation and apoptosis | Sponge miR-34a | GFRA1 | NR | [29] |
| circGFRA1 | cytoplasm | Microarray of TNBC cells and MCF-10A/51 TNBC versus 51 N/222 TNBC | RT-qPCR    | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS, DFS | Proliferation and apoptosis | Sponge miR-34a | GFRA1 | NR | [29] |
| hsa_circ_0006528 | NR | MDA-MB-231/DOX | qRT-PCR    | MDA-MB-231/DOX | Up in MDA-MB-231/DOX | Oncogenic | Prediction of therapy response | NR | NR | Increase the resistance of TNBC cells to PTX | Sponge miR-17-5p | Ral1 | NR | [87] |

TNBC: triple-negative breast cancer, N: normal, DOX: doxorubicin, PTX: paclitaxel, 5-FU: 5-fluorouracil, MDA-MB-231/PTX: PTX-resistant MDA-MB-231, MDA-MB-231/DOX: DOX-resistant MDA-MB-231, MDA-MB-231/monastrol: monastrol-resistant MDA-MB-231, 5-FU-resistant MDA-MB-231, S-FU: survival, DFS: disease-free survival, AUC: area under the curve, NR: not report, ISH: in situ hybridization, qRT-PCR: quantitative real-time PCR.
CircRNAs interact with RBPs
CircRNAs could specifically bind to proteins directly or through RNA as well as sequester proteins to block the protein effects by working as competing elements (Fig. 3b) [65]. One classic example of circRNA to interact with proteins is circFoxo3. It’s expression significantly promoted TNBC cell apoptosis with upregulation of Foxo3, but downregulation of p53. Mechanically, circFoxo3 preferred to bind MDM2 and p53, instead of Foxo3 in MDA-MB-231 cells. As such, circFoxo3 overexpression promoted MDM2-induced p53 ubiquitination and subsequent degradation, but competitively prevented MDM2-mediated Foxo3 ubiquitination and degradation, eventually leading to cell apoptosis due to upregulation of the Foxo3 downstream target PLUMA [66]. Moreover, circRNAs are able to bind and sequester proteins. For example, circMTO1 interacted with TRAF4 by serving as a ceRNA to repress TRAF4 from binding to the Eg5 gene, leading to sequester TRAF4 from activating Eg5 translation, thus mediating TNBC cell resistance to monastrol [67].

CircRNAs encode proteins
CircRNAs were previously regarded as a distinct class of endogenous non-coding RNAs that could not translate proteins due to lack of 5–3 polarity, a polyadenylated tail, and an internal ribosome entry site (IRES). However, recent studies indicated that some cytoplasmic circRNAs can be effectively translated into detectable peptides [68, 69]. IRES- and N(6)-methyladenosines-mediated cap-independent translation initiation have been suggested to be potential mechanism for circRNA translation [70, 71]. To date, several circRNAs have been uncovered to have the potential to be translated into proteins, for instance, circZNF609, circPABPN1 [72, 73]. In TNBC (Fig. 3c), circFBXW7 not only can serve as a sponge of miR-197-3p to upregulate its parent gene FBXW7, but also encode the FBXW7-185aa protein to increase the abundance of FBXW7, thereby promoting c-Myc ubiquitination and degradation, eventually suppressing TNBC cells growth and metastasis [74]. More recently, Li et al. confirmed that a newly identified HER2 transcriptional variant, circHER2, had an open reading frame driven by an IRES and could generate a 103 amino acid protein HER2–103. HER2–103 could promote homo/hetero dimerization of epidermal growth factor receptor (EGFR)/HER3 and sustain AKT phosphorylation and downstream malignant phenotype [75]. Whith the increasing evidence prove that circRNAs could translate proteins directly [72, 73, 76, 77], the notion of circRNAs are non-coding RNAs is becoming doubtful.

Role of circRNAs on the biological functions of TNBC
CircRNAs play an important role in the regulation of cell proliferation, invasion, metastasis, apoptosis, autophagy, cell cycle, vascularization, and chemoresistance of TNBC by regulating the expression of target genes involved in cancer-related signaling pathways directly or indirectly. The biological roles of circRNAs involved in TNBC cells are depicted and summarized in Fig. 4.

CircRNAs modulate TNBC proliferation and tumor growth
Majority circRNAs identified in TNBC are characterized by oncogenic features. Specifically, circRPPH1, circSEPT9, circGFB1, circPGAP3, circUBE2D2, circRAD18, circAGFG1, circKIF4A, circPLK1, circUBAP2, circEPSTI1, and circGFA1I were upregulated in both TNBC cells and tissues, and high expression of these circRNAs was able to promote tumor cell proliferation both in vitro and in vivo, and was associated with larger tumor sizes and shorter survival times for TNBC patients [29, 46, 49, 51, 53, 54, 57, 59, 60, 63, 64, 78]. Similarly, circZEB1, circEIF3M, circHER2, hsa_circ_0131242, hsa_circ_0005320, hsa_circ_069718, hsa_circ_0058514, and circTFCP2L1 were overexpressed in TNBC cells and tissues, and they appeared to promote cell proliferation and tumor growth of TNBC [55, 58, 62, 75, 79–82]. On the contrary, a few circRNAs were identified to have tumor-suppressive effects in TNBC. For example, circFBXW7, circTADA2A-E6, circITCH, and circAHNAK1 were found to be down-regulated in TNBC cells and tissues. Their expression was negatively correlated with the tumor sizes and DFS or OS of TNBC patients, and ectopic overexpression of these circRNAs obviously inhibited cell proliferation and tumor growth [48, 52, 56, 74]. Lisewise, circCDYL was down-regulated in TNBC cells and inhibited proliferation of TNBC cells [61].

CircRNAs affect invasion and metastasis of TNBC
Certain circRNAs also play pivotal roles in promoting the invasion and metastasis of TNBC. High expression of circSEPT9, circGFB1, circAGFG1, circPGAP3, circKIF4A, circPLK1, circANKS1B, and circRPPH1 significantly contributed to the invasion and metastasis of TNBC cells both in vitro and in vivo, and were correlated with advanced TNM stage and poor prognosis of TNBC patients [45, 47, 49, 51, 53, 54, 57, 59, 64]. Likewise, circRPPH1, hsa_circ_0131242, circEIF3M, circHER2, hsa_circUBE2D2, circRAD18, hsa_circ_069718, hsa_circ_0058514, and circTFCP2L1 also significantly promoted the migration and invasion capability of TNBC cells in vitro [55, 60, 62, 63, 75, 78, 79, 81, 82]. Conversely, the expression of circFBXW7, circAHNAK1,
circTADA2A-E6, and circITCH appeared to be downregulated in TNBCs and was associated with advanced TNM stage and poor survival for TNBC patients [48, 52, 56, 74]. Ectopic overexpression of circFBXW7, circAHNAK1, and circITCH markedly inhibited the migration of TNBC cells in vitro and obviously reduced the size and number of lung metastasis nodules in xenograft models of TNBC [52, 56, 74]. Epithelial-to-mesenchymal transition (EMT) is a process characterized by the loss of the polarity and adhesion capacity of epithelial cells, but an increase in the mesenchymal traits [83], which is pivotal for TNBC cells to metastasize [84]. Notably, circRPPH1, hsa_circ_069718, circKIF4A, and circPLK1 could increase the expression of mesenchymal marker vimentin and decrease the expression of epithelial marker E-cadherin, thus contributing to EMT and metastasis [51, 54, 60, 81]. Wnt/β-catenin pathway is a key signaling cascade tightly associated with cancer progression. Activation of the Wnt/β-catenin pathway could promote tumor invasion by the upregulation of factors regulating the EMT processes [85]. We found that hsa_circ_069718 and circITCH have opposite roles in regulating the Wnt/β-catenin pathway. Hsa_circ_069718 activated the Wnt/β-catenin pathway by upregulating β-catenin, c-Myc, and cyclin D1 and thus promoted the invasion and metastasis of TNBC cells, while circITCH played the opposite role [52, 81]. Besides, circANKS1B was proved to promote EMT via increasing the expression of transcription factor USF1, which could transcriptionally upregulate TGF-β1 expression, resulting in activating TGF-β1/Smad signaling [47]. On the contrary, circTADA2A-E6 exerted a negative effect on the regulation of metastasis by suppressing the EMT process [48]. Above all, these circRNAs might act as potential predictors and therapeutic targets for metastatic TNBC.

**CircRNAs regulate apoptosis of TNBC cells**

CircSEPT9, circZEB1, circEIF3M, hsa_circ_0005320, circRAD18, circGFRAla1, hsa_circ_0058514, circAGFG1, circUBAP2, and circEPSTI1 have been proven to be upregulated in TNBC cells and tissues, and associated with decreased cell apoptosis rates of TNBC cells [29, 46, 49, 53, 57, 58, 62, 78, 80, 82]. Silencing of circSEPT9, hsa_circ_0005320, or circAGFG1 leads to typical apoptotic morphological characteristics in TNBC cells, such as nuclear shrinkage as well as apoptotic body and nuclear fragmentation [49, 57, 80]. Mechanically, knockdown of circSEPT9, circZEB1, or circAGFG1 could increase the protein levels of the apoptotic markers (cleaved caspase 3 and Bax) while decrease the anti-apoptotic marker...
(Bcl-2) levels in TNBC cells [49, 57, 58]. Taken together, these circRNAs may mediate the progress of TNBC by suppressing tumor cell apoptosis.

**Cell cycle/autophagy/angiogenesis-associated circRNA in TNBC**

It is well known that CCNE1 works by forming a complex with CDK2, and the CCNE1-CDK2 complex is able to pushing cell cycle from G1 to S phase, thereby regulating tumor progression [86]. *Hsa_circ_0058514* and *circAGFG1* were proved significantly up-regulated in TNBC cells and tissues and could promote the CCNE1 and CDK2 expression via acting as miRNAs sponge, the knockdown of *hsa_circ_0058514* and *circAGFG1* resulted in G1/S phase cell cycle arrest [57, 82]. Similarly, *circEIF3M* acts as a ceRNA to upregulate CCND1, which mainly coordinates with cyclin-dependent kinase 4 (CDK4) to regulate cell cycle progression, downregulation of circEIF3M led to G1 arrest [62]. Besides, silencing *hsa_circ_0005320* led to higher percentages of TNBC cells being arrested in the G1 phase, with lower percentages of cells in the S phase, suggesting *hsa_circ_0005320* also exerts functions in the regulation of the cell cycle of TNBC cells [80]. Meanwhile, Yang et al. also discovered that *circAGFG1* significantly promoted tumor angiogenesis, suggesting *circAGFG1* also play important roles in the regulation of tumor angiogenesis [57]. *CircRPPH1* was proved to facilitates angiogenesis in TNBC as well [60]. As for autophagy, the knockdown *circSEPT9* in TNBC cells could increase the conversion of the autophagy marker LC3 from LC3-I to LC3-II and upregulate the autophagy-related proteins ATG5 and ATG7, thereby inducing LC3II punctuation and accumulation of autophagosomes [49].

**CircRNAs regulate TNBC resistance to therapeutic drugs**

Chemotherapy is a critical strategy for TNBC treatment, which is usually administered as postoperative therapy or preoperative neoadjuvant therapy. The most commonly used chemotherapeutics, including anthracyclines (doxorubicin[DOX] and epirubicin), taxanes (PTX and docetaxel), 5-fluorouracil (5-FU), and cyclophosphamide, have achieved substantial advantages for TNBC patients, but do not work out for every patient due to drug resistance [4]. CircRNAs have been reported to play vital roles in drug resistance, either by promoting or reversing TNBC chemoresistance [87].

DOX-based chemotherapy is the most frequently used treatment for TNBC [88]. *Hsa_circ_0006528, circKDM4C, circUBE2D2*, and *circLARP4* were found to be associated with DOX resistance in TNBC [63, 87, 89, 90]. Specifically, *hsa_circ_0006528* was significantly upregulated in DOX-resistant MDA-MB-231 (MDA-MB-231/DOX) cells [87], mechanically by participating in the *circ_0006528/miR-7-5p/Raf1* axis that confers chemotherapeutic resistance in TNBC [91]. Likewise, *circUBE2D2* decreased DOX-induced TNBC cells apoptosis by upregulating CDCA3, which is a trigger of mitotic entry to withstand the DOX-induced apoptosis, indicating that *circUBE2D2* promotes DOX resistance of TNBC cell [63]. Instead, *circLARP4* was downregulated in TNBC cell lines, and ectopic overexpression of *circLARP4* can increase the sensitivity of MDA-MB-231 cell lines to DOX [89]. In addition, *circKDM4C* expression was significantly decreased in MDA-MB-231/DOX cells and could attenuate DOX resistance by upregulating *PBLD* [90], which is a tumor suppressor that could inhibit tumor growth [92].

Chemoresistance against PTX is one of the major issues related to treatment failure in TNBC patients. However, the mechanism by which TNBC cells become resistant to PTX remains unclear. Recently, three circRNAs, *CircGFRA1, circABCB10* and *circAMOTL1*, were identified as important factors that may be responsible for the adverse resistance to PTX in TNBC cells. Specifically, *CircGFRA1* and *circABCB10* were upregulated in the PTX-resistant MDA-MB-231 (MDA-MB-231/PTX) cells. *CircGFRA1* knockdown can inhibit the resistance of TNBC cells to PTX by reducing the expression of *TLR4*, which has been found to be activated by paclitaxel to improve tumor cell survival and blocking TLR4 could significantly improve response to paclitaxel therapy in BC [50, 93]. *CircABCB10* contributed to PTX resistance of TNBC cells through up-regulating of *DUSP7*, which exerts its function by dephosphorylating MAPK [94, 95]. Besides, *circAMOTL1* promoted the chemoresistance against PTX in TNBC cells via posttranscriptional regulation of AKT and therefore led to increase the anti-apoptotic gene *BCL2* expression and inhibit the pro-apoptotic gene *BAX* and *BAK* expression [96].

Moreover, *circ-CDR1as* was found to be associated with 5-FU-resistant in MDA-MB-231 cells by inhibiting *miR-7* to upregulate *CCNE1* [97]. Besides, *circMT01*, which is usually downregulated in monastrol-resistant MDA-MB-231 cells, can promote monastrol-induced cytotoxicity by targeting Eg5 and sequestering *TRAF4* from binding to the Eg5 gene [67]. Interestingly, *circHER2*, which encodes a novel protein HER2–103, was proved to be expressed in some TNBC samples, and HER2–103-positive TNBC cells were sensitive to Pertuzumab due to HER2–103 shared the same amino acid sequences as the HER2 CR1 domain [75].

More and more circRNAs are being identified to be associated with chemoresistance, however, our understanding of the mechanistic role of circRNAs contributing to chemotherapeutic resistance is limited due to
lack of deep mechanistic investigations and in vivo studies. Whether circRNAs could be a potential target for overcoming TNBC chemo-resistance requires further exploration.

**Clinical significance of circRNAs in TNBC**

CircRNAs have also been proven to possess potential values for diagnosis and prognosis of TNBC. As a result, circRNAs have received considerable interest for their potential as prognostic markers or therapeutic targets.

**CircRNAs acts as diagnostic biomarkers for TNBC**

There are six circRNAs have been currently identified to have diagnostic values in TNBC. Among them, three circRNAs were upregulated and the other three were downregulated in TNBC (Table 2). *CircAHNAK1* was the first identified circRNA that significantly downregulated in TNBC tissues, therefore it can be used as a diagnostic indicator for distinguishing TNBC from normal breast tissue [56]. Xu et al. [48] identified two differentially expressed circ*TADA2A*s, *circTADA2A-E6* and *circTADA2A-E5/E6*, that were spliced from exon 6 or exons 5 and 6 of the same *TADA2A* gene respectively, in TNBc, and found that these two circRNAs were significantly downregulated in TNBC and exhibited excellent diagnostic values. Besides, *circAGFG1*, *circRAD18*, and *circSEPT9* were found to be upregulated in TNBC and also exhibited excellent ability in discriminating between TNBC patients and normal individuals [49, 57, 78].

**Association of circRNAs with clinicopathological features of TNBC**

Based on the current reported evidences, we summarized the relationship between circRNAs expression and the clinicopathological factors of TNBC in Additional file 1: Tables S1 and S2. Accordingly, there was no significant correlation between any circRNAs expression and age or menopause status of TNBC patients (Additional file 2: Figure 1). While many circRNAs expression was significantly associated with other clinical parameters of TNBC, including tumor size, lymph node metastasis, histological grade, and TNM stage (Table 3). More importantly, the expression levels of *circSEPT9*, *circGNB1*, hsa_circ_0131242, *circPGAP3*, *circRAD18*, *circAGFG1*, *circKIF4A*, *circPLK1*, *circUBAP2*, *circ-ciRS-7*, *circEPSTI1*, and *circGFRA1* were positively correlated with the tumor size [29, 45, 46, 49, 51, 53, 54, 57, 59, 60, 64, 78, 79], whereas *circFBXW7*, *circAHNAK1*, and *circITCH* presented negative associations (Fig. 5a) [52, 56, 74]. *CircAGFG1* and *circGFRA1* were positively related to

---

### Table 2 Summary of diagnosis values of circRNAs in TNBC

| CircRNAs       | TNBC samples | Normal samples | Expression in TNBC | Method  | Sample type | AUC   | Sensitivity | Specificity | References |
|----------------|--------------|----------------|--------------------|---------|-------------|-------|-------------|-------------|------------|
| circSEPT9      | 60           | 60             | Up                 | RT-qPCR | Tissue      | 0.711 | 0.633       | 0.75        | [49]       |
| circRAD18      | 31           | 31             | Up                 | RT-qPCR | Tissue      | 0.752 | NR          | NR          | [78]       |
| circAGFG1      | 40           | 40             | Up                 | RT-qPCR | Tissue      | 0.767 | NR          | NR          | [57]       |
| circTADA2A-E6  | 115          | 16             | Down               | RT-qPCR | Tissue      | 0.8554| NR          | NR          | [48]       |
| circTADA2A-E5/E6 | 115       | 16             | Down               | RT-qPCR | Tissue      | 0.9366| NR          | NR          | [48]       |
| circAHNAK1     | 20           | 20             | Down               | RT-qPCR | Tissue      | 0.72  | NR          | NR          | [56]       |

TNBC: triple-negative breast cancer, NR: not report, qRT-PCR: quantitative real-time PCR, AUC: area under the curve

---

### Table 3 Summary of circRNAs related to clinicopathological features of TNBC

| Clinicopathological factors | Correlation of circRNAs expression with clinicopathological factors in TNBC |
|-----------------------------|--------------------------------------------------------------------------------|
|                             | Positive                                                                 | Negative                                                                 |
| Tumor size                  | circSEPT9, circGNB1, hsa_circ_0131242, circPGAP3, circRAD18, circAGFG1, circKIF4A, circPLK1, circUBAP2, circ-ciRS-7, circEPSTI1, circGFRA1 | circFBXW7, circAHNAK1, circITCH                                           |
| Histological grade          | circAGFG1, circGFRA1                                                            | NR                                                                      |
| LN metastasis               | circRPPH1, circSEPT9, circPGAP3, circUBE2D2, circAGFG1, circKIF4A, circPLK1, circANKS1B, circUBAP2, circ-ciRS-7, circEPSTI1, circGFRA1 | circUSP42, circFBXW7, circTADA2A-E6, circAHNAK1, circITCH               |
| TNM stage                   | circSEPT9, circGNB1, hsa_circ_0131242, circPGAP3, circUBE2D2, circRAD18, hsa_circ_069718, circKIF4A, circPLK1, circANKS1B, circUBAP2, circEPSTI1 | circUSP42, circTADA2A-E6, circAHNAK1, circITCH                           |

TNBC: triple-negative breast cancer, NR: not report, LN: lymph node
the histological grade of TNBC (Fig. 5b) [29, 57]. High expressions of circRPPH1, circSEPT9, circAGFG1, circPGAP3, circLBE2D2, circKIF4A, circANKS1B, circUBAP2, circ-ciRS-7, circEPSTI1, and circGFRA1 were associated with positive lymph node metastasis [29, 45–47, 51, 53, 54, 57, 60, 63, 64], while low expressions of circUSP42, circFBXW7, circTADA2A-E6, circAHNAK1, and circITCH were associated with positive lymph node metastasis in TNBC (Fig. 5c) [48, 52, 56].

CircRNAs act as prognostic biomarkers for BC

21 circRNAs have been reported to have the prognostic values for TNBC patients (Table 4). Specifically, high expression of circSEPT9, circGANBI, circRAD18, circAGFG1, and circANKS1B and low expression of circFBXW7 were related to worse survival of TNBC and could be independent prognostic factors for TNBC patients [47, 49, 57, 59, 74, 78], while circTADA2A-E6 was frequently downregulated in TNBC and whose downregulation were associated with worse survival (Fig. 6).

### Fig. 5

Forest plots of the associations between the expression of circRNAs and a tumor sizes (> 2 vs ≤ 2), b histological grade (III vs I + II), c lymph node metastasis (positive vs negative), d TNM stage (III + IV vs I + II) of TNBC. Each square indicates a study. * indicates > 5 versus ≤ 5, # indicates III + II versus I, OR odds ratio, CI confidence interval
Table 4 Summary of significant associations of circRNAs with TNBC survival

| CircRNAs     | Roles    | TNBC Patients | Expression | Method     | Sample type | Cut off     | Univariate versus multivariate | Survival | HR (95% CI)         | Reference |
|--------------|----------|---------------|------------|------------|-------------|-------------|--------------------------------|----------|-----------------------|-----------|
| circSEPT9    | Oncogenic| 80            | Up         | ISH        | Tissue      | 6           | Multivariate                    | OS       | 3.042 (1.278–7.240), 𝑃<0.012 | [49]      |
| circUSP42    | Antitumor| 30            | Down       | RT-qPCR    | Tissue      | Median      | Univariate                      | OS, DFS  | 2.148 (1.070–4.310), 𝑃<0.031 | [59]      |
| circGNB1     | Oncogenic| 222           | Up         | RT-qPCR    | Tissue      | NR          | Multivariate                    | OS       | 2.148 (1.070–4.310), 𝑃<0.031 | [59]      |
| hsa_circ_0131242 | Oncogenic| 120           | Up         | RT-qPCR    | Tissue      | NR          | Univariate                      | OS       | KM                    | [79]      |
| circ-HER2    | Oncogenic| 59            | Up         | RT-qPCR    | Tissue      | > Adjacent  | Univariate                      | OS       | KM                    | [75]      |
| circPGAP3    | Oncogenic| 86            | Up         | RT-qPCR    | Tissue      | Median      | Univariate                      | OS, DFS  | KM                    | [64]      |
| circUBED2    | Oncogenic| 66            | Up         | RT-qPCR    | Tissue      | Median      | Univariate                      | OS       | KM                    | [63]      |
| circRAD18    | Oncogenic| 126           | Up         | RT-qPCR    | Tissue      | Median      | Multivariate                    | OS       | 2.045 (1.010–4.143), 𝑃<0.041 | [78]      |
| circAGFG1    | Oncogenic| 80            | Up         | ISH        | Tissue      | Median      | Multivariate                    | OS       | 6.072 (2.614–14.105), 𝑃<0.001 | [37]      |
| circFBXW7    | Antitumor| 473           | Down       | RT-qPCR    | Tissue      | Mean        | Multivariate                    | OS, DFS  | 0.215 (0.119–0.387), 𝑃<0.001 | [48]      |
| circTADA2A-E6| Antitumor| 115           | Down       | RT-qPCR    | Tissue      | NR          | Univariate                      | OS, DFS  | 0.088 (0.011–0.714), 𝑃<0.023; DFS, 0.094 (0.012–0.770), 𝑃<0.028 | [48]      |
| has_circ_069718 | Oncogenic| 35            | Up         | RT-qPCR    | Tissue      | NR          | Univariate                      | OS       | KM                    | [81]      |
| circAHNAK1   | Antitumor| 136           | Down       | RT-qPCR    | Tissue      | Median      | Univariate                      | OS, DFS  | KM                    | [56]      |
| circITCH     | Antitumor| 91            | Down       | RT-qPCR    | Tissue      | Median      | Univariate                      | OS       | KM                    | [52]      |
| circTFCP2L1  | Oncogenic| 32            | Up         | RT-qPCR    | Tissue      | − 6.58      | Univariate                      | DFS      | KM                    | [55]      |
| circKIF4A    | Oncogenic| 240           | Up         | RT-qPCR    | Tissue      | Mean        | Univariate                      | OS, DFS  | KM                    | [51]      |
| circPLK1     | Oncogenic| 240           | Up         | RT-qPCR    | Tissue      | Mean        | Univariate                      | OS, DFS  | KM                    | [51]      |
| circANKS1B   | Oncogenic| 165           | Up         | RT-qPCR    | Tissue      | Median      | Multivariate                    | OS       | 3.29 (1.75–8.23), 𝑃<0.008 | [47]      |
| circUBAP2    | Oncogenic| 78            | Up         | RT-qPCR    | Tissue      | Median      | univariate                      | OS       | KM                    | [53]      |
| circEPST1I   | Oncogenic| 240           | Up         | ISH        | Tissue      | NR          | univariate                      | OS, DFS  | KM                    | [46]      |
| circGFA1     | Oncogenic| 222           | Up         | RT-qPCR    | Tissue      | Mean        | univariate                      | OS, DFS  | KM                    | [29]      |

TNBC triple-negative breast cancer, OS overall survival, DFS disease-free survival, NR not report, qRT-PCR quantitative real-time PCR, ISH in situ hybridization, HR hazard ratio, CI confidence interval
circPLK1, circANKS1B, circUBAP2, circEPSTI1, and circGFRA1) was related to worse OS [46, 47, 49, 51, 53, 54, 57, 59, 63, 64, 75, 78, 79, 81], indicating that they have carcinogenic effects in TNBC. Increased expression of the 5 circRNAs (circUSP42, circFBXW7, circTADA2A-E6, circAHNAK1, and circITCH) was associated with better OS for TNBC patients [48, 52, 56, 74, 98], suggesting that they serve as tumor suppressors. In terms of DFS, elevated expression of 7 circRNAs (circGNB1, circPGAP3, circTFCP2L1, circKIF4A, circPLK1, circEPSTI1, and circGFRA1) showed reduced DFS [29, 46, 51, 54, 55, 59, 64], while high circUSP42, circTADA2A-E6, circFBXW7, and circAHNAK1 expression predicted better DFS [48, 56, 74, 98], implying that they are related to the recurrence or progression of TNBC.

Conclusions and perspective

TNBC represents a more malignant and aggressive subtype of BC that lacks of effective targeted therapies, and the specific pathogenesis of TNBC is still not fully understood. CircRNAs, previously thought to be the products of RNA splicing errors, are now regarded as an emerging vital player with intriguing functions during various physiological and pathophysiological processes. As discussed in this review, the exact mechanisms of circRNAs maturation have not been fully elucidated, while the dysregulation of circRNAs is believed to be one of the important mechanisms leading to the development and progression of TNBC. As regulators of gene expression, circRNAs are involved in various biological processes of TNBC, including cell proliferation, apoptosis, cell cycle, angiogenesis, metastasis and chemoresistance, making them potential promising biomarkers for TNBC in regard to diagnosis, prognosis or treatment.

Besides, there are several gaps in the research field of circRNA in TNBC, which need to be further fulfilled in the future. CircRNAs are always maintained at a relatively stable state in cells and they live long in the extracellular environment owing to their unique structures that are resistant to exonuclease RNase R and [32, 99], identification of dysregulated circRNAs in body fluids, therefore, may be more beneficial for the diagnosis and prognosis of TNBC. Currently, circRNAs in clinical samples, such as plasma, serum, or exosomes have been found to be serve as significant biomarkers in tumor. For example, Wang et al. have identified and validated a number of dysregulated circRNAs in exosomes from BC patients [100] and circUBE2D2 was found to
significantly load in exosomes isolated from tamoxifen-resistant cells, which reinforced tamoxifen resistance in BC [101]. Nevertheless, there is no literature reporting the circulating circRNAs (from blood, urine, saliva, etc.) in TNBC, which should be pursued in future researches. Additionally, the well-known mechanism of circRNAs exerting functions in biological or pathological processes is through ceRNA to target downstream genes, while other potent molecular mechanisms of circRNAs involved in TNBC progression is limited and needs further investigation. Moreover, other unexcavated circRNAs related to TNBC development and progression and elucidation of their corresponding functions are also awaiting for discovery.

Overall, this review gives a systematically summary of the biogenesis, regulatory mechanisms, and biological functions of circRNAs in TNBC, and lists almost all of the circRNAs that dysregulated in TNBC and discusses their significant values for TNBC in regarding to diagnosis, prognosis and chemoresistance, which provides great guiding significance for future researches of circRNAs in TNBC. A better understanding of circRNAs in TNBC may contribute to the development of more reliable diagnosis and treatment strategies for TNBC.

Abbreviations
BC: Breast cancer; TNBC: Triple-negative breast cancer; ER: Estrogen receptor; PR: Progesterone receptor; HER2: Human epidermal growth factor receptor 2; TAMs: Tumor-associated macrophages; miRNAs: MicroRNAs; IncRNAs: Long non-coding RNA; circRNAs: Circular RNAs; RNA-seq: RNA sequencing; qRT-PCR: Quantitative real-time PCR; pre-mRNAs: Precursor messenger RNAs; EcircRNAs: Fusion circRNAs; RBPs: RNA-binding proteins; ceRNAs: Competing endogenous RNAs; mRNAs: Messenger RNAs; IRES: Internal ribosome entry site; EMT: Epithelial-to-mesenchymal transition; DOX: Doxorubicin; MDA-MB-231/DOX: DOX resistant MDA-MB-231; PTX: Paclitaxel; MDA-MB-231/PTX: PTX resistant MDA-MB-231; S-FU: S-Fluorouracil; OS: Overall survival; DFS: Disease-free survival.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13045-021-01052-y.

Acknowledgements
We thank all members of our study team for their wonderful cooperation.

Authors’ contributions
LJL, SZ Z, M W collected the related paper. LJ L and XY D drafted and wrote the manuscript. SZ Z and YJ D revised the manuscript. ZJ D, Y W, and SY participated in the design of the review and helped to draft and revise the manuscript. All authors read and approved the final manuscript.

Funding
This study was funded by none institution or individual.

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China. 2 Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China. 3 The Cancer Institute of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.

Received: 17 December 2020 Accepted: 25 February 2021

References
1. Li N, Deng Y, Zhou L, Tian T, Yang S, Wu Y, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017. J Hematol Oncol. 2019;12(1):140.
2. Ahmad A. Breast cancer statistics: recent trends. Adv Exp Med Biol. 2019;1152:1–7.
3. Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2015;35:e31–9.
4. Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015;121(1):8–16.
5. Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161(2):279–87.
6. Hwang SY, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple-negative breast cancer. Pharmacol Ther. 2019;199:30–57.
7. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38(6):698–707.
8. Mei J, Hao L, Wang H, Xu R, Liu Y, Zhu Y, et al. Systematic characterization of non-coding RNAs in triple-negative breast cancer. Cell Prolif. 2020;53:e12801.
9. Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci USA. 1976;73(11):3852–6.
10. Capel B, Swain A, Nicolis S, Hacker A, Walter M, Koopman P, et al. Circular transcripts of the testis-determining gene Sry in adult mouse testis. Cell. 1993;73(5):1019–30.
11. Pasman Z, Been MD, Garcia-Blanco MA. Exon circularization in mammalian nuclear extracts. RNA (New York, NY). 1996;2(6):603–10.
12. Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56(1):55–66.
13. Wang PL, Bao Y, Yee MC, Barrett SR, Hogan GJ, Olsen MN, et al. Circular RNA is expressed across the eukaryotic tree of life. PLoS ONE. 2014;9(6)e90859.
14. Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32(5):453–61.
15. Chaabane M, Andreeva K, Hwang JY, Kook TL, Park JW, Cooper NGF. seekCRIT: detecting and characterizing differentially expressed circular RNAs using high-throughput sequencing data. PLoS Comput Biol. 2020;16(10):e1008338.

16. Hansen TB, Vena MT, Damgaard CK, Kjems J. Comparison of circular RNA prediction tools. Nucleic Acids Res. 2016;44(6):e58.

17. Zhou R, Wu Y, Wang W, Su W, Liu Y, Wang Y, et al. Circular RNAs (circRNAs) in cancer. Cancer Lett. 2018;425:134–42.

18. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–8.

19. Lei K, Bai H, Wei Z, Xie C, Wang J, Li J, et al. The mechanism and function of circular RNAs in human diseases. Exp Cell Res. 2018;368(2):147–58.

20. Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21(8):475–90.

21. Tang Q, Hann SS. Biological roles and mechanisms of circular RNA in human cancers. OncoTargets Ther. 2020;13:2067–92.

22. Shan C, Zhang Y, Hao X, Gao J, Chen X, Wang K. Biogenesis, functions and clinical significance of circRNAs in gastric cancer. Mol Cancer. 2019;18(1):136.

23. Marotti JD, de Areu FB, Wells WA, Tsongalis GJ. Triple-negative breast cancer: next-generation sequencing for target identification. Am J Pathol. 2017;187(10):2133–8.

24. Li Z, Chen Z, Hu G, Zhang Y, Feng Y, Jiang Y, et al. Profiling and integrated analysis of differentially expressed circRNAs as novel biomarkers for breast cancer. J Cell Physiol. 2020;235:7945–59.

25. Nair AA, Niu N, Tang X, Thompson KJ, Wang L, Kocher JP, et al. Circular RNAs and their associations with breast cancer subtypes. Oncotarget. 2016;7(49):80967–79.

26. Yuan C, Zhou L, Zhang L, Yin K, Peng J, Sha R, et al. Identification and integrated analysis of key differentially expressed circular RNAs in ER-positive subtype breast cancer. Epigenomics. 2019;11(3):297–321.

27. Zhou SY, Chen W, Yang SJ, Xu ZH, Hu JH, Zhang HD, et al. The emerging role of circular RNAs in breast cancer. Biosci Rep. 2019;39(6):1.

28. Geng X, Jia Y, Zhang Y, Shi L, Li Q, Zang A, et al. Circular RNA-biogenesis, degradation, functions and potential roles in mediating resistance to anticancer. Epigenomics. 2020;12(3):267–83.

29. He R, Liu P, Xie X, Zhou Y, Liao Q, Xiong W, et al. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. J Exp Clin Cancer Res CR. 2017;36(1):145.

30. Kristensen LS, Andersen MS, Stagsted LW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–91.

31. Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71(3):428–42.

32. Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25(8):981–4.

33. Wang Q, Li Z, Hu Y, Zheng W, Tang W, Zhou L, et al. circTFCP2L1 promotes the proliferation and migration of triple negative breast cancer through sponging miR-7 by inhibiting PKX1. J Mammary Gland Biol Neoplasia. 2019;24(4):323–31.

34. Pei X, Wang X, Xue B, Zhang Y, Sun M, Li H. Circular RNA circ-ZEB1 acts as an oncogene in triple negative breast cancer via sponging miR-448. Int J Biochem Cell Biol. 2020;126:105723.

35. Liu P, Zou Y, Li X, Yang A, Ye F, Zhang J, et al. circNR1B1 facilitates triple-negative breast cancer progression by regulating miR-512-3p/CDCA3 axis. Cancer Cell Int. 2020;20:454.

36. Du D, Ren Z, Han M, Xu X, Ge X, Gu Y, et al. circUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple negative breast cancer by regulating miR-512-3p/CDCA3 axis. Cancer Cell Int. 2020;20:454.
64. He D, Yang X, Kuang W, Huang G, Liu X, Zhang Y. The novel circular RNA Circ-PGAP3 promotes the proliferation and invasion of triple negative breast cancer by regulating the miR-330-3p/Myc axis. Oncotargets Therapy. 2020;13:10149–59.

65. Du WW, Zhang C, Yang W, Yong T, Awan FM, Yang BB. Identifying and characterizing circRNA-protein interaction. Theranostics. 2017;17(17):4183–91.

66. Du WW, Fang L, Yang W, Wu N, Awan FM, Yang Z, et al. Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity. Cell Death Differ. 2017;24(2):357–70.

67. Liu Y, Dong Y, Zhao L, Su L, Luo J. Circular RNA-MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF6/EG5 axis. Int J Oncol. 2018;53(4):1752–62.

68. Lei M, Zheng G, Ning Q, Zheng J, Dong D. Translation and functional roles of circular RNAs in human cancer. Mol Cancer. 2020;19(1):30.

69. Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Strotmeyer C, Ruhe L, et al. Translation of CircRNAs. Mol Cell. 2017;66(1):9-21.e7.

70. Chen CY, Sarnow P. Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. Science (New York, NY). 1995;268(5209):415–7.

71. Abdelmohsen K, Panda AC, Munk R, Grammatikakis I, Dudekula DB, De L, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 2017;14(3):361–9.

72. Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther. 2013;12(8):1676–87.

73. Zhang M, Zhao K, Xu X, Yang Y, Yan S, Wei P, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 2017;14(3):361–9.

74. Zou Y, Zheng S, Xiao W, Xie X, Yang A, Gao G, et al. circRAD18 sponges tumor progression and attenuates doxorubicin resistance by regulating miR-7-5p and activating the MAPK/ERK signaling pathway. Mol Carcinog. 2019;58(4):554–64.

75. Li A, Yan Q, Zhao X, Zhong J, Yang H, Feng Z, et al. Decreased expression of FBXL1 correlates with poor prognosis and functions as a tumor suppressor in human hepatocellular carcinoma. Oncotarget. 2016;7(11):5234–7.

76. Rajput S, Volk-Drepper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther. 2013;12(8):1676–87.

77. Lu H, Zhu X, Wang S, Song Y, Zhou S, Lin J, et al. Long non-coding RNA MiAT promotes breast cancer progression and functions as ccelRNA to regulate DUSP7 expression by sponging miR-135-5p. Oncotarget. 2017;8(44):76153–64.

78. Yang W, Geng P, Yang Y, Yang C, Yang B, Ren I. Circ-ABC10 contributes to paclitaxel resistance in breast cancer through let-7a-5p/DUSP7 axis. Cancer Manag Res. 2020;12:2327–37.

79. Li J, Fang L, Yang Q, Hibberd S, Du WW, Wu N, et al. Posttranscriptional regulation of AKT by circular RNA angiopoietin-like 1 mediates chemoresistance against paclitaxel in breast cancer cells. Aging. 2019;11(23):11369–81.

80. Yang W, Gu J, Wang X, Wang Y, Feng M, Zhou D, et al. Inhibition of circular RNA CORD1 enhances chemosensitivity of S-FU-resistant BC cells through up-regulating miR-7. J Cell Mol Med. 2019;23(5):1611–9.

81. Yu J, Shen W, Xu J, Gong B, Gao B, Zhu J. circ(SPA2) is downregulated in triple-negative breast cancer and associated with poor prognosis. Technol Cancer Res Treat. 2020;19:1533033820950827.

82. Hsiao KY, Sun HS, Tsai SJ. Circular RNA—a new member of noncoding RNA family. Epigenomics. 2019;11(4):479–505.

83. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96.

84. Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13:395–412.

85. Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–99.

86. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene. 2005;24(17):2776–86.

87. Gao D, Zhang X, Liu B, Meng D, Fang K, Guo Z, et al. Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics. 2017;9(9):1175–88.

88. Rampurwala MM, Rocque GB, Burkard ME. Update on adjuvant chemotherapy for early breast cancer. Breast Cancer Basic Clin Res. 2014;8:125–33.

89. Zhang X, Su X, Guo Z, Jiang X, Li Y. Circular RNA La-related RNA-binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer. J Clin Lab Anal. 2020;34(7):e23272.